Masashi Takahara,* Manami Miyai,* Mai Tomiyama,* Masato Mutou,* Andrew J. Nicol, and Mie Nieda*,1

Size: px
Start display at page:

Download "Masashi Takahara,* Manami Miyai,* Mai Tomiyama,* Masato Mutou,* Andrew J. Nicol, and Mie Nieda*,1"

Transcription

1 Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8 T cells via V 9 T cell activation Masashi Takahara,* Manami Miyai,* Mai Tomiyama,* Masato Mutou,* Andrew J. Nicol, and Mie Nieda*,1 *Medinet Medical Institute, Tokyo, Japan; and Centre for Immune and Targeted Therapy, University of Queensland, Greenslopes Private Hospital, Brisbane, Australia Abstract: We demonstrate that V 9 T cells activated by zoledronate can link innate and acquired immunity through crosstalk with dendritic cells (DCs) in a way that can amplify activation and proliferation of tumor antigen-specific CD8 T cells. DCs pulsed with antigen alone or antigen plus zoledronate were used to stimulate the in vitro expansion of antigen-specific CD8 T cells. MART-1-modified peptide (A27L peptide) and apoptotic HLA-A*0201-positive, MART-1-positive JCOCB tumor cell lines were used as tumor antigen sources. The percentage of A27L-specific CD8 T cells within the responding lymphocytes on Day 7 when immature DCs (imdcs) were cultured in the presence of A27L peptide and 0.01 M zoledronate was significantly higher (P 0.002, n 11) than that observed when imdcs were cultured with the lymphocytes in the presence of the A27L peptide alone. This enhancing effect of zoledronate was significantly reduced when T cells were depleted from responding lymphocytes (P 0.030, n 5), indicating that the effect is mediated mainly through V 9 T cells activated by zoledronatepulsed imdcs. When imdcs copulsed with zoledronate and apoptotic JCOCB tumor cell lines were used, the percentage of A27L-specific CD8 T cells was higher than that observed using imdcs with the apoptotic JCOCB lines alone, suggesting that zoledronate treatment of imdcs enhances the cross-presentation ability of DCs. These findings suggest a potentially valuable role for V 9 T cell activation for expanding antigen-specific CD8 T cells using DCs copulsed with tumor antigen and zoledronate in the design of vaccine therapies for malignancy. J. Leukoc. Biol. 83: ; Key Words: human CTLs adjuvants aminobisphophonates infectious agents not eradicated by the natural immune response. New methods to increase the immune response and a greater understanding of all components of the antigen-specific immune response are needed for further therapeutic progress. CTLs are the most efficient cells for specifically and directly killing malignant or infected cells. Therefore, one of the goals of an effective immunotherapy against cancer or infectious diseases is the induction of a strong antigen-specific CTL response [1, 2]. Dendritic cell (DC) therapy, aimed at stimulating tumor- or viral antigen-specific CTL in vivo, frequently induces a measurable immune response. However, clinical responses are seen in a minority of patients, presumably, at least in part, as a result of insufficient expansion of antigenspecific CTLs capable of eradicating tumor cells or virally infected cells. Despite major advances in our understanding of the adaptive immune system s activity against tumors or infectious agents, many conventional vaccine delivery systems and adjuvants approved for human use are relatively poor at inducing antigen-specific CD8 CTL responses [1 6]. Immune responses are generally divided into innate and acquired responses. Accumulating evidence indicates that multiple interactions commonly occur between immune effector cells, and these are crucial for the initiation as well as the outcome of these immune responses [7]. For successful immunotherapy, it is crucial to marshal and orchestrate a vast array of effector cells, including conventional T cells (CTLs), T cells, NK cells, and invariant NKT cells (inkt cells). DCs play a pivotal role in bridging innate and acquired immunity by facilitating crosstalk between such effector cells, directly or indirectly through cytokines derived from effector cells and DCs. This interplay provides opportunities for immune effector cells to play an adjuvant role, enhancing antigen-specific T cell responses. Adjuvant effects of inkt cell activation on antigen-specific CTLs have been demonstrated in murine models [8]. We have recently shown that the inkt cells activated by -galactosylceramide-pulsed DCs can bridge innate and acquired immunity to induce activation and proliferation of INTRODUCTION Immunotherapy against tumors or infectious agents is based on the concept that a rapid or vigorous, therapeutically induced immune response will be able to effectively control tumors or 1 Correspondence: Medinet Medical Institute, Medinet Co., Ltd., Seta, Setagaya-ku, Tokyo, , Japan. nieda@medinet-inc.co.jp Received March 23, 2007; revised November 15, 2007; accepted November 21, doi: /jlb Journal of Leukocyte Biology Volume 83, March /08/ Society for Leukocyte Biology

2 IFN- -producing CD8 T cells in the human system [9]. Also, it has been shown that NK cells interact with DCs and engage in an active crosstalk, inducing DC maturation through cytokines secreted by NK cells, thereby promoting acquired immune responses [10, 11]. Characterization of T cells provided the first evidence for a lymphocyte subset that could interface innate and acquired immunity [7, 12, 13]. However, it has not been clearly demonstrated that T cells can also interact with DCs in a way that results in active crosstalk inducing acquired immune responses, in particular, induction of antigen-specific CTL responses. Since the fortuitous discovery of T cells about two decades ago, many articles have been written that address the biology of these lymphocytes in animal and human models [14]. In humans, most of our knowledge about the specificity and biological role of T cells is derived from analysis of a major peripheral subset referred to as V 9V 2 T cells, comprising 5 10% of all circulating T cells. There is growing evidence for cytotoxic antitumor activities of V 9V 2 T cells against a large range of tumor types [15 17]. The V 9V 2 T cells express and use NK cell-activating receptors, such as NKG2D, recognizing targets expressing stress-inducible NKG2D ligands MHC class I chain-related antigens A and B (MICA and MICB) and UL-16-binding proteins [18 20]. After target cell recognition, cytotoxicity is generally mediated by the perforin/granzyme pathway [21, 22]. Unlike classical T cells, the V 9V 2 T cells can interact with low molecular mass phosphate-containing, nonprocessed antigens, such as pyrophosphomonoesters [23] and alkyl amine [24]. Recently, aminobisphosphonates, such as pamidronate and zoledronate, were also shown to activate V 9V 2 T cells, and the aminobisphosphonate-activated V 9V 2 T cells were functionally characterized in vitro and in vivo [25 29]. The activated V 9V 2 T cells rapidly release Th1 cytokine such as IFN- and TNF-, enhancing antitumor activity by inhibiting tumor growth and activating components of the adaptive immune system [30, 31]. In contrast to pyrophosphomonoesters, the V 9V 2 T cell activation by aminobisphophonates is highly dependent on the presence of APCs including DCs [32 34]. Aminobisphosphonates appear to target the mevalonate pathway of the APCs and induce the accumulation of phosphorylated metabolites, such as isopentenyl pyrophosphate, which are recognized by the V 9V 2 T cells. As described above, it is well known that aminobisphosphonate-activated V 9V 2 T cells have potent antitumor cytotoxicity and that DCs act as cellular bridges between innate and acquired immunity, interacting with NK cells or inkt cells. However, little is known about whether aminobisphosphonate-activated V 9V 2 T cell effects on DCs could modulate immune responses mediated by conventional T cells, in particular, by tumor antigen-specific CD8 CTL [34, 35]. The aim of this study was to investigate whether V 9V 2 T cells activated by zoledronate-pulsed DCs can link innate and acquired immunity in a way that can amplify activation and proliferation of tumor antigen-specific CD8 T cells. We describe a role for zoledronate in efficiently enhancing DCinduced expansion of antigen-specific CD8 CTLs and provide evidence for a role of T cells in enhancing acquired tumor antigen-specific immunity. We highlight the implications of the cellular crosstalk between DCs and T cells on the design of immune-based therapies for control of cancer and infection. MATERIALS AND METHODS Antibodies and reagents The cell surface phenotype of T cells, T cells, and DCs was determined by single or two-color flow cytometry using the Epics XL MCL (Beckman Coulter, Erembodegem, Belgium), and data were analyzed using ADC software (Beckman Coulter). The following mab were used for flow cytometry: anti- CD14-PE, anti-hla-dr-pe, anti-cd83-pe, anti-cd40-pe, anti-tcrv 9- FITC, anti-tcrv 9-PE, anti-tcrv 2-FITC, anti-tcr -PE, anti-cd3- PC5, anti-cd40 ligand (CD40L)-PE, anti-cd54-pe, anti-cd80-pe, and anti- CD62L-PE from Beckman Coulter; anti-cd8-fitc, anti-hla-abc-pe, and anti-cd86-pe from BD Biosciences (San Jose, CA, USA); and anti-ccr7 from R&D Systems (Minneapolis, MN, USA). The purified mab specific for IFN- mab was obtained from BD Biosciences. Isotype-matched controls were also obtained from Beckman Coulter and BD Biosciences. Zoledronate was purchased from Novartis Pharmaceuticals (Basel, Swiss). HLA-A*0201-restricted, modified MART-1 (A27L) 10mer synthetic peptides (ELAGIGILTV) and A27L tetramer were obtained from Operon (Tokyo, Japan) and MBL (Nagoya, Japan), respectively. HLA-A*0201-positive, MART-1-positive tumor cell line (JCOCB) was kindly provided as a gift by Dr. Chris Schmidt at the Queensland Institute of Medical Research (Brisbane, Australia). This cell line was originally established from fresh surgical specimens. Generation of DCs and cell culture Peripheral blood (PB) samples were collected from healthy donors possessing HLA-A*0201. The study was approved by the Ethics Committee of the Seta Clinic (Tokyo, Japan). All subjects provided written, informed consent. PBMCs were isolated by density gradient centrifugation with Lymphoprep (Nycomed, Oslo, Norway). For cell culture in this study, AIM-V medium (Invitrogen, Tokyo, Japan), supplemented with 10% heat-inactivated human AB serum, was used. CD14-positive monocytes were purified from PBMCs by positive selection with anti-cd14 mab using MACS (Miltenyi Biotec, Bergich Gladbach, Germany). Monocytes were cultured with 500 U/mL recombinant IL-4 (Osteogenetics GmbH, Würzburg, Germany) and 500 U/mL recombinant GM- CSF (Immunex, Richmond, CA, USA) for 5 days to obtain what are referred to in this manuscript as immature DCs (imdcs). Mature DCs (mdcs) were generated from this population by adding a proinflammatory cytokine cocktail containing IL-1 (10 ng/ml, Chemicon International, El Segundo, CA, USA), TNF- (10 ng/ml, BD Pharmingen, Franklin Lakes, NJ, USA), IL-6 (10 ng/ml, R&D Systems), and PGE 2 (1 g/ml, Sigma, Tokyo, Japan) for a further 48 h. The cells defined as imdcs in this study were CD14, HLA-DR, HLA-ABC, CD80, CD86, CD40, CD54, CD83 (weak), and CCR7 (very weak). mdcs were CD14, HLA-ABC, HLA-DR, CD80, CD86, CD40, CD54, CD83, and CCR7. CD14-negative populations following MACS were used as responding lymphocytes. Initial assessment of V 9 T cell proliferation by zoledronate in the presence of imdcs or mdcs PB lymphocytes (CD14-negative fraction) from healthy donors were cultured with imdcs or mdcs in the presence of zoledronate at different concentrations (0.01 M, 0.1 M, and 1 M) in the presence of IL-2 (50 U/mL, Chiron Benelux B.V., The Netherlands). These concentrations of zoledronate were chosen from our previous unpublished observations, showing that the optimal concentration of zoledronate to expand V 9 T cells, when PBMCs were cultured for 7 days in the presence of zoledronate, was between 0.01 M and 1 M. The percentage of V 9 T cells in expanding lymphocytes was assessed on Day 7 using flow cytometry. The percentage of V 9 T cells in the PB lymphocytes varied between 0.85% and 13%, depending on individuals in this experiment. It has been reported that the V 9 chain is in most cases paired to the V 2 [36]. We have confirmed that the phenotype of almost all (90 98%) zoledronate-activated V 9 T cells in PB lymphocytes was V 2- Takahara et al. DCs pulsed with tumor antigen and zoledronate 743

3 positive in our experiments (data not shown), and therefore, anti-tcrv 9 mab was used to detect the phenotype of T cells throughout this study. Assessment of adjuvant effects of zoledronate on inducing and expanding tumor antigen-specific CD8 T cells DCs were cultured with autologous lymphocytes in the presence of A27L peptide (2 g/ml), with or without zoledronate at various concentrations. IL-2 (50 U/mL) was added to the cultures every 2 3 days. The final concentrations of zoledronate evaluated were 0.01 M, 0.1 M, and 1 M as zoledronic acid. Briefly, imdcs or mdcs were cultured in the presence or absence of zoledronate, and subsequently, A27L peptide was added. Following overnight culture, autologous lymphocytes were added to the DC culture. The percentage of A27L-specific CD8 T cells in the total lymphocytes was assessed on Days 7 and 14 using A27L/HLA-A*0201 tetramer. The total cell numbers of A27L-specific CD8 T cells were calculated using the total cell numbers of the expanding lymphocytes on Days 7 and 14. In some experiments, the percentage of V 9 T cells as a fraction of total lymphocytes was assessed using FITC-conjugated anti-tcrv 9 mab. The expression of CD40L on V 9 T cells was assessed on Days 0, 3, 7, and 14 following coculture of imdcs with autologous lymphocytes in the presence of peptide (2 g/ml), with or without zoledronate (0.01 M). Alternatively, imdcs were cultured overnight in the presence or absence of zoledronate (0.1 M) with A27L peptide or apoptotic JCOCB cell lines, and then, the imdcs extensively washed with media, prior to coculturing them with autologous lymphocytes. Apoptosis of JCOCB cell lines was induced by allowing culture overgrowth, resulting in 40% apoptotic cells, according to the percentage of Annexin V-positive cells, which were stained using an Annexin V-FITC kit (Immunotech, Marseilles, France), according to the manufacturer s protocol using flow cytometry. During culture, IL-2 (20 U/mL) was added every 3 4 days. To assess the phenotype of pulsed DCs following coculture with lymphocytes in the presence of zoledronate, imdcs were cultured with autologous lymphocytes in the presence of A27L peptide, with or without zoledronate (0.01 M) for 48 h. The expression for CCR7 and CD62L molecules on DCs was assessed by flow cytometry with gating on the DCs, defined by scatter properties and lineage negativity. Assessment of the role of T cells in the adjuvant effects of zoledronate To assess the role of T cells in the adjuvant effects of zoledronate, experiments were conducted in which the numbers of T cells and other candidate populations in the responding populations were controlled. Two different series of experiments were performed. In one series of experiments, T cells were enriched by negatively selecting for T cells using the Pan T cell isolation kit (MACS). The enriched T cell populations were separated from the T cell-enriched populations by negative selection with anti- mab using MACS. The negatively selected cells remaining after the second of these two MACS separation were predominantly ( 99%) T cells. The enriched T cell populations were separated from the T cell-enriched populations by negative selection using the anti-tcr MicroBead kit (MACS). The resulting T cell populations, containing 99% T cells, were cocultured with A27L-pulsed imdcs (with or without zoledronate), and varying numbers of the enriched T cells returned to the responder cell populations. Varying concentrations of enriched T cells (respectively, , ,5 10 4, , and ) were added to purified T cells. This resulted in responder populations in which 99% of cells were T cells or T cells in controlled, defined ratios (with T cell percentage of 1%, 2.5%, 5%, 10%, and 45%). The combined cell populations were cocultured with imdcs in the presence of IL-2 and A27L (2 g/ml), with or without zoledronate (0.01 M) for 7 days. The percentage of A27L-specific T cells was evaluated by flow cytometry. In another series of experiments, the response of lymphocyte populations, in which T cells were depleted from responder populations by positive selection with anti- T cell mab using MACS, was assessed. We confirmed by flow cytometry that more than 98% of T cells were depleted from starting lymphocytes. Stimulator imdcs were unpulsed or pulsed with A27L or A27L and zoledronate, and the pulsed imdcs were washed extensively prior to the addition of the responder populations. Cultures were performed in the presence of added IL-2 but not additional A27L or zoledronate. The percentages of A27L-specific CD8 T cells were determined by flow cytometry after 7 days as described above. ELISPOT assays To evaluate the effect of zoledronate on antigen-specific T cells, imdcs were cultured with autologous lymphocytes in the presence or absence of zoledronate at 0.01 M with A27L peptide (2 g/ml). Following 7 days culture, the numbers of antigen-specific, IFN- -producing cells were determined by ELISPOT after 16 h in vitro restimulation of the cultured lymphocytes using the same conditions (imdcs and A27L peptide, with or without zoledronate) as were used for the first stimulation. ELISPOT assays were conducted, in triplicate, according to the manufacturer s instructions (Mabtech AB, Nacka Strand, Sweden). The plates were counted using the Autoimmun Diagnostika system (AID; Autoimmun Diagnostika GmbH, Strassberg, Germany), and data were analyzed using AID software. Cytokine analysis The levels of IFN- in culture supernatant following coculture of imdcs with autologous lymphocytes in the presence of peptide, with or without zoledronate (0.01 M), were assessed at 48 h and 72 h using ELISA (Immunotech), according to the manufacturer s instructions. The assay was performed in triplicate, and the detection limit of IFN- is 0.08 IU/mL. CTL assay Fluorochromasia cell-mediated cytotoxicity testing was carried out using Terascan VPC (Minerve Tech, Tokyo, Japan) as described previously [37, 38] In brief, of target cells (JCOCB cell lines) in 1 ml were labeled for 45 min with 10 L calcein-am solution (Dojindo Laboratories, Kumamoto, Japan). The target cells were washed twice and then incubated with effectors at different E:T ratios for 4 h using 96-well half-area flat plates with lid (3696, Corning Inc., Corning, NY, USA) in triplicate. Cytotoxic activity was evaluated by the release of fluorochromasia into the medium. Viability of JCOCB target cells prior to assay was more than 91%. The JCOCB target cells used in this assessment were HLA-ABC, MICA/B, CD86 (weak), HLA-DR-negative, and CD80-negative. Blocking studies with mab To evaluate mechanisms of cytotoxic activity against JCOCB target cells, purified, blocking mab, including anti-mhc class I (W6/32, BioLegend, San Diego, CA, USA), anti-dr (G46-6, BD PharMingen) and anti-mica (6D4, BioLegend), were used at 10 g/ml to block the relevant cytotoxic pathways. The antibodies were added to effector cells 30 min prior to coculture with target cells. Mouse IgG2a (BD PharMingen) was used as controls. The results were expressed as mean SD counts of three cultures. Statistical analysis P values were calculated using the paired Student s t-test and considered significant at a P value 0.05 and highly significant at a P value RESULTS imdcs have greater capacity to expand PB V 9 T cells in the presence of zoledronate than mdcs APCs are essential for aminobisphosphonate-induced expansion of V 9V 2 T cells [32 34]. We first compared the relative capacity of imdcs and mdcs as APCs to expand T cells using the aminobisphosphonate, zoledronate at 0.01 M, 0.1 M, and 1 M. The results indicate that zoledronateinduced expansion of V 9 T cells was greater in the presence of imdcs than in the presence of mdcs at each of the three concentrations of zoledronate (Fig. 1A). The percentage 744 Journal of Leukocyte Biology Volume 83, March

4 of V 9 T cells on Day 0 in the PB lymphocytes was 5%, and this did not increase following culture with imdcs or mdcs without zoledronate (Fig. 1A). Also, V 9 T cells did not expand in the absence of APCs, such as imdcs or mdcs (data not shown), as previously shown [32 34]. Further, the expansion of V 9 T cells from four to six different donors at three different concentrations of zoledronate was significantly greater using imdc than mdc [*, P for 0.01 M (n 4), **, P for 0.1 M (n 6), and ***, P for 1 M (n 5; Fig. 1B)]. In view of these observations, the following experiments were mostly performed using imdcs. Zoledronate enhances imdc-induced expansion of A27L-specific CD8 T cells using A27L peptide To examine the adjuvant effects of zoledronate on inducing and expanding tumor antigen-specific CD8 T cells, we initially assessed generation of antigen-specific CD8 T cells using imdcs in the presence of A27L peptide (2 g/ml), with or without zoledronate at different concentrations ( M) and different culture durations (7-day culture vs. 14-day culture; Fig. 2A). Among the different concentrations evaluated, imdcs cultured with autologous lymphocytes in the presence of the A27L peptide with 0.01 M zoledronate for 14 days resulted in the highest total numbers of A27L-specific CD8 T cells (A27L cells) and the highest percentage of A27Lspecific CD8 T cells as a fraction of total lymphocytes (Fig. 2A). The numbers and the percentage of A27L-specific CD8 T cells within the responding lymphocytes when imdcs were cultured in the presence of A27L peptide and 0.01 M zoledronate were 90- and 100-fold higher, respectively, than that observed when imdcs were cultured with the lymphocytes in the presence of A27L peptide alone following 14-day culture (Fig. 2A). Results from 11 independent experiments using PBMCs from seven different donors showed the percentage of A27L-specific CD8 T cells stimulated by imdcs in the presence of A27L peptide and 0.01 M zoledronate on Day 7 was significantly higher (P 0.002, n 11) than that produced by imdcs in the presence of A27L peptide alone (Fig. 2B). In multiple independent experiments using PBMCs collected on different days from the same donor, the results were similar (data not shown). Considering the results shown in Figures 1A and 2, most of the following experiments were performed using imdcs with 0.01 M zoledronate. In some cases, we also evaluated zoledronate at 0.1 M, as this concentration also had adjuvant effects (Fig. 2A). Using higher concentration of zoledroante with 10 M in the presence of A27L peptide, the percentage of V 9 T cells in the expanding PB lymphocytes was much higher than that with 0.01 M zoledronate and A27L peptide; however, the percentage of A27L-specific CD8 T cells in the expanding PB lymphocytes was much less than that with 0.01 M zoledronate and A27L peptide (data not shown). We also assessed the percentage of V 9 T cells in responding lymphocytes following coculture with imdcs in the presence of A27L peptide, with or without zoledronate. The percentage of V 9 T cells in responding lymphocytes when stimulated with imdcs in the presence of A27L peptide with 0.01 M zoledronate for 7 days was approximately threefold higher (Donors 5 and 6) than that observed when imdcs were pulsed with A27L peptide alone (Fig. 2C, left). To evaluate the effects of zoledronate on expansion of lymphocytes, including A27L-specific CD8 T cells and V 9 T cells, which may be associated with the cytokine production of responding lymphocytes, we assessed IFN- production by the expanding lymphocytes using ELISPOT assays. The results showed that when imdcs were cultured in the presence of zoledronate and A27L peptide for 7 days, total IFN- -producing cell numbers per 2500-expanding lymphocytes were two-fold higher (Donor 5) and 17-fold higher (Donor 6) than that observed when imdcs were pulsed with A27L peptide alone (Fig. 2C, right). PBMCs were cultured for 7 days with imdcs in the presence of A27L Fig. 1. (A) Zoledronate-induced expansion of V 9 T cells using imdcs and mdcs. DCs (from Donor 1) were cultured with autologous-responding lymphocytes (L) in the presence of zoledronate at 0.01 M, 0.1 M, and 1 M, respectively, and the percentage of V 9 cells in the lymphocytes was assessed on Day 7 using flow cytometry. The results are representative of four to six experiments at three different concentrations with similar results. (B) Expansion of V 9 T cells was significantly greater in response to imdcs than mdcs at all three different concentrations of zoledronate [*, P for 0.01 M (n 4), **, P for 0.1 M (n 6), and ***, P for 1 M (n 5)]. The percentage of V 9 cells in the responding lymphocytes (on Day 0) varied between 0.85% and 13% depending on individuals. Takahara et al. DCs pulsed with tumor antigen and zoledronate 745

5 Fig. 2. Zoledronate enhances imdc-induced expansion of A27L-specific CD8 T cells using A27L peptide. imdcs were cultured with autologous lymphocytes in the presence of A27L peptide (2 g/ml), with or without zoledronate (Z) at different concentrations ( M). The numbers and the percentage of A27L-specific CD8 T cells (A27L cells) in the proliferated lymphocytes were determined on Days 7 and 14, as described in Materials and Methods. (A) imdcs (from Donor 7), cultured with autologus lymphocytes in the presence of the A27L peptide with zoledronate (0.01 M) for 14 days, resulted in the highest percentage of A27L-specific CD8 T cells (A27L cells) and the highest numbers of A27L cells. A27L-specific CD8 T cells on Day 0 in the PB lymphocytes were 0.03%. (B) The percentage of A27L-specific CD8 T cells (A27L cells) stimulated by imdcs for 7 days in the presence of A27L peptide with 0.01 M zoledronate was increased significantly in comparison with that by imdcs in the presence of A27L peptide alone. Shown are the results from 11 independent experiments using PB lymphocytes from seven different donors (P 0.002, n 11). (C) The percentage of expanding V 9 T cells in the responding lymphocytes following coculture with imdcs in the presence of A27L peptide and zoledronate increased, in parallel with the increased percentage of A27L-specific CD8 T cells (A27L cells; left). IFN- -producing cell numbers in the expanding lymphocytes increased significantly when stimulated by imdcs in the presence of A27L peptide with zoledronate in comparison with that stimulated by imdcs in the presence of A27L peptide alone (right). imdcs (Donors 5 and 6) were cultured with autologous lymphocytes in the presence or absence of zoledronate at 0.01 M with A27L peptide (2 g/ml). Following 7 days culture, the percentages of A27L-specific CD8 T cells (A27L cells, dark, shaded bars) and V 9 T cells ( T cells, light, shaded bars) in the proliferated lymphocytes were determined using flow cytometry, and IFN- -producing cell numbers (numbers of spots, dotted bars) per 2500 of the proliferated lymphocytes were determined using ELISPOT assay. Data are mean values of triplicate samples. (D) The percentages of A27L-specific CD8 T cells and V 9 T cells in the proliferated lymphocytes when cultured with imdcs in the presence of A27L peptide and 0.01 M zoledronate on Day 7 were significantly higher than those observed by imdcs in the presence of A27L peptide alone [n 13, P for V 9 T cells ( T cells, light, shaded bars), and P for A27L-specific CD8 T cells (A27L cells, dark, shaded bars)]. 746 Journal of Leukocyte Biology Volume 83, March

6 peptide and 0.01 M zoledronate in 13 independent experiments from five donors. The results showed the percentages of A27L-specific CD8 T cells and V 9 T cells to be significantly higher (P for A27L-specific CD8 T cells and P for V 9 T cells) in cultures containing zoledronate than that observed in cultures containing A27Lpeptide alone (Fig. 2D). We assessed IFN- production by the expanding lymphocytes from two additional donors using ELISPOT assays. The results were similar to those from Donors 5 and 6 (described in the previous section), showing that when imdcs were cultured in the presence of zoledronate and A27L peptide for 7 days, total IFN- -producing cell numbers were higher than that observed when imdcs were pulsed with A27L peptide alone (data not shown). It has been reported that the cytotoxic activity of expanded CTLs correlates with the frequency of melanoma tetramerbinding CD8 T cells [39]. However, to verify our own tetramer results, we assessed the antigen-specific cytotoxic activity of the expanding lymphocytes responding to imdcs cultured in the presence of A27L peptide with zoledronate. As it has previously been shown that A27L tetramer-positive CD8 T cells fully cross-recognize the natural MART-1 peptide and are able to efficiently lyse MART-1-expressing tumor cell lines [40], we used the JCOCB cell line expressing MART-1 as target cells for this assessment. Various E:T ratios (40:1, 20:1, and 10:1) were evaluated. We also confirmed that the JCOCB cell line expressed MICA molecules, which are ligands for NKG2D on T cells. The results show that the cytotoxic activity against the JCOCB by the lymphocytes, expanded in zoledronate containing cultures for 7 days, was greater than for the lymphocytes expanded without zoledronate ( % vs %, respectively, at an E:T ratio of 40:1). The T cell populations in zoledronate-containing cultures contained higher frequencies of A27L tetramer-positive T cells (3.03%) and of V 9 T cells (5.97%) following 7 days culture than in cultures without zoledronate with 1.07% of A27L tetramerpositive cells and 4.50% of V 9 T cells (Fig. 3A). To assess the relative contribution of antigen-specific cytotoxic CD8 T cells and V 9 T cells in the observed cytotoxicity, blocking experiments were performed. The cytotoxic activity of expanded lymphocytes containing 3.03% of A27L tetramer-positive cells and 4.50% of V 9 T cells was assessed at an E:T ratio of 40:1 in the presence of anti-mhc class I, anti-mica, anti-hla-dr mab, and mouse IgG2a antibody as controls. Inhibition of killing was % and % for anti-mhc class I and anti-mica mab, respectively. There was no inhibition in controls using anti-hla-dr and IgG2a antibodies (Fig. 3B). This suggests that A27L tetramer-positive CD8 T cells contributed more to the killing of the target cells than V 9 T cells. Two individuals were evaluated with similar results being obtained. V 9 T cells play a crucial role in the zoledronate-induced adjuvant effects for expansion of A27L-specific CD8 T cells To investigate a role of T cells in the increased expansion of A27L-specific CD8 T cells, imdcs were cultured with autologous-responding T cells consisting of T cells and Fig. 3. The cytotoxic activity of the expanded lymphocytes against the MART-1-positive tumor cell line, JCOCB, is higher in populations containing higher frequencies of A27L-specific CD8 T cells (3.03%) and V 9 T cells (5.97%) following culture with imdcs in the presence of A27L peptide with zoledronate (0.01 M; imdc/a27l Z) in comparison with that in populations containing lower frequencies of A27L-specific CD8 T cells (1.07%) and V 9 T cells (4.50%) following culture with imdcs in the presence of A27L peptide alone (imdc/a27l). Data are mean values of triplicate samples. Cytotoxic activity was assessed as described in Materials and Methods. The cytotoxic activity of the expanded lymphocytes containing populations of A27L-specific CD8 T cells and V 9 T cells against JCOCB tumor cell lines was blocked by anti-mhc class I and anti-mica mab. The cytotoxic activity of expanded lymphocytes containing of 3.03% of A27L tetramer-positive cells and 4.50% of V 9 T cells against JCOCB tumor cell lines was assessed at an E:T ratio of 40:1 in the presence of anti-mhc class I, anti-mica, anti-hla DR mab, and mouse IgG2a antibody as controls. Takahara et al. DCs pulsed with tumor antigen and zoledronate 747

7 T cells in different ratios for 7 days. The results show that the numbers of A27L-specific CD8 T cells generated from three donors increased in parallel with the increased percentage of T cells added in the responding T cells ( T cells T cells) in the presence of zoledronate but not in the absence of zoledronate (Fig. 4A). This suggests that the activation/expansion of V 9 T cells plays a crucial role of V 9 T cells in the zoledronate-induced adjuvant effects on expansion of A27L-specific CD8 T cells. To further confirm the role of T cells in the zoledronate-induced adjuvant effects through DCs, T cells were depleted from unmanipulated responding lymphocytes. As shown in Figure 4B, the enhancing effect of zoledronate was reduced significantly when T cells were depleted from lymphocytes when imdcs were cultured in the presence of peptide with zoledronate for 7 days (P 0.030, n 5, using PBMCs from three donors), indicating again that the adjuvant effects of zoledronate are mediated primarily through zoledronate-activated V 9 T cells. This enhancing effect of zoledronate-activated V 9 T cells was reduced significantly when anti-ifn- mab was added in the coculture medium (P 0.016, n 5; Fig. 4B). These results indicate that although other cytokines may also be involved in zoledronateinduced adjuvant effects, IFN- induced by activated V 9 T cells seems to be a critical cytokine. In this experiment, the percentage of V 9 T cells in unmanipulated-responding lymphocytes was %, and that in V 9 T cell-depleted, responding lymphocytes was %. We hypothesized that IFN- induced by activated T cells may play an important role in the induction of zoledronateinduced adjuvant effects. Therefore, we tested whether the percentages of A27L-specific CD8 T cells and V 9 T cells increased when imdcs were cultured in the presence of A27L peptide (2 g/ml) and IFN- (1 100 U/mL). The results show that when IFN-, at a concentration of 1 U/mL [a similar concentration to that detected in the supernatant after culturing lymphocytes with imdcs in the presence of zoledronate and A27L peptide (see below)] or higher (100 U/mL), was added directly into the culture medium, there was no increases in the percentages of both A27L-specific CD8 T cells (Fig. 4C). Induction of CD40L on V 9 T cells in responding lymphocytes following coculture with imdcs in the presence of peptide with zoledronate Whereas CD40 is expressed constitutively on DCs, macrophages and B cells, CD40L is induced on activated T cells, including CD4 T cells, CD8 T cells, inkt cells and NK cells [41 47]. It has been clearly shown that the linkage of innate to acquired immunity through the interaction of DCs interacting with inkt cells to induce antigen-specific CD8 T cells requires CD40 ligation on DCs by CD40L-expressing inkt cells [45]. We hypothesized that expression of CD40L on T cells could be induced following stimulation by imdcs copulsed with zoledronate and that this contributed to enhance- Fig. 4. (A) The number of A27L-specific CD8 T cells (A27L cells) generated increased in parallel with the increased percentage of T cells added in the responding T cells ( T cells and T cells) when cultured with imdcs in the presence of A27L peptide (P) and zoledronate (Z). Final percentages of T cells in the responding T cell were 1%, 2.5%, 5%, 10% and 45%. imdcs, T cells and T cells were prepared from Donors 07, 08 and 10, respectively. (B) The enhancing effect of zoledronate was decreased significantly when T cells were depleted from responding lymphocytes (L- T; P 0.030) and was reduced significantly when anti-ifn- was added into the culture medium (P 0.016). imdcs were cultured with autologous lymphocytes at 0.01 M and A27L peptide. In blocking experiments, anti-ifn- mab (10 g/ml) or isotype-matched control (IgG1) was added in the coculture medium of imdcs with autologous lymphocytes in the presence of A27L peptide and zoledronate. Following 7 days culture, expansion fold of A27L-specific CD8 T cells (A27L cells) was determined. (C) There were no increases in the percentages of A27L-specific CD8 T cells (A27L cells) and V 9 T cells following culture with imdcs in the presence of A27L peptide and IFN-. imdcs were cultured with autologous lymphocytes in the presence of IFN- (1 and 100 U/mL) with A27L peptide. Following 7 days culture, the percentages of A27L-specific CD8 T cells (A27L cells) and V 9 T cells in the proliferated lymphocytes were determined. 748 Journal of Leukocyte Biology Volume 83, March

8 ment of the induction of antigen-specific CD8 T cells. To evaluate this possibility, we assessed the expression level of CD40L on V 9 T cells before stimulation (Day 0) and at various time intervals (Days 3, 7, and 14) following coculture with imdcs in the presence of A27L peptide (2 g/ml), with or without zoledronate (0.01 M). As shown in Figure 5A, the expression of CD40L on V 9 T cells was dependent on the duration of stimulation, and the highest expression (39.8%) was detected on Day 7 following stimulation with imdcs in the presence of A27L peptide with zoledronate. Following further culture, CD40L expression on V 9 T cells decreased, going down to 8.5% by Day 14. In contrast, the expression of CD40L on V 9 T cells in the presence of A27L peptide alone was minimally increased on Day 7, increasing from 4.6% on Day 0 to 7.6% on Day 7. Results from four independent experiments using PBMCs from three different donors showed the expression of CD40L on V 9 T cells stimulated by imdcs in the presence of A27L peptide with zoledronate on Day 7 to be significantly higher (P ) than that stimulated by imdcs in the presence of A27L peptide alone (Fig. 5B). These results indicate that zoledronate copulsing was important for up-regulation of CD40L on V 9 T cells and consequently for efficient induction of antigen-specific CD8 T cells via CD40- expressing DCs. Although CD40 is constitutively expressed on DCs, in one donor assessed, the expression of CD40 on DCs was slightly greater based on mean fluorescent intensity (MFI) following coculture with imdcs in the presence of A27L peptide with zoledronate than that following coculture in the presence of A27L peptide alone (63.5 for imdc/a27l peptide vs for imdc/a27l peptide zoledronate). Considering the results shown in Figure 5A, the numbers of V 9 T cells in the expanding lymphocytes were assessed on Days 7 and 14 following coculture with imdcs in the presence of A27L peptide (2 g/ml) and zoledronate (0.01 M), in parallel with the numbers of A27L-specific CD8 T cells. Although expansion of V 9 T cells was higher on Day 7 than that on Day 14 when imdcs were copulsed with A27L peptide and zoledronate, the expansion of A27L-specific CD8 T cells was higher on Day 14 than that on Day 7 (Fig. 5C). The data are mean values ( SD) from triplicate cultures and are representative of three independent experiments from different donors. To evaluate for a possible role of IFN- in the observed up-regulation of CD40L, we evaluated CD40L expression on V 9 T cells after culture of autologous lymphocytes with imdcs in the presence of A27L peptide (2 g/ml) with IFN- at two different concentrations (100 and 1000 U/mL). The results show that the expression of CD40L on V 9 T cells slightly increased on Day 7 ( % for 100 U/mL and % for 1000 U/mL), but this was much less than that observed after culture with imdcs in the presence of A27Lpeptide and zoledronate ( %; Fig. 5, A and D) IFN- production in the culture supernatant following coculture of imdcs with lymphocytes in the presence of A27L peptide with zoledronate To further investigate a potential role for reciprocal activating interactions between DCs and aminobisphosphonates-stimulated T cells [34], we assessed IFN- production in the culture supernatants following coculture of imdcs with lymphocytes in the presence of A27L peptide, with or without zoledronate for 48 h and 72 h. The results show that IFN- production was only detected in the presence of A27L peptide Fig. 5. (A) The expression of CD40L on V 9 T cells was dependent on the duration of stimulation with imdcs in the presence of A27L peptide with zoledronate. imdcs (from Donor 7) were cultured with autologous lymphocytes in the presence of A27L peptide, with or without zoledronate at 0.01 M. The expression of CD40L on V 9 T cells was assessed on Days 0, 3, 7, and 14 using flow cytometry. (B) The expression of CD40L on V 9 T cells stimulated by imdcs in the presence of A27L peptide with zoledronate on Day 7 was significantly higher than that stimulated by imdcs in the presence of A27L peptide alone. Shown are the results from four independent experiments using PB lymphocytes from three donors (P , n 4). (C) Although expansion of V 9 T cells was higher on Day 7 than that on Day 14 following coculture of autologous lymphocytes with imdcs in the presence of A27L peptide and zoledronate, the expansion of A27L-specific CD8 T cells was higher on Day 14 than that on Day 7. The total numbers of A27L-specific CD8 T cells (A27L cells) and V 9 T cells were calculated using total numbers of the proliferated lymphocytes and the percentages of both populations in the lymphocytes on Days 7 and 14. (D) The expression of CD40L on V 9 T cells after culture with imdcs in the presence of A27L peptide and IFN- was much less than that observed after culture with imdcs in the presence of A27L peptide and zoledronate. imdcs were cultured with autologous lymphocytes in the presence of A27L peptide and IFN- (100 or 1000 U/mL), and the expression of CD40L on V 9 T cells was assessed on Day 7. Takahara et al. DCs pulsed with tumor antigen and zoledronate 749

9 A27L peptide and zoledronate, in which IFN- production was detected as described above. The results showed that upregulation of CD62L was observed in all three donors assessed, and CCR7 up-regulation was observed in two out of three donors assessed. Again, depletion of V 9 T cells from the responding lymphocytes partially abrogated up-regulation of CD62L and CCR7. The results shown in Figure 6B (referring to one representative experiment from Donor 7) showed that expression of CCR7 and CD62L molecules on DCs increased following copulsing with zoledronate ( % for CCR7 and % for CD62L) and fell following depletion of T cells from responding lymphocytes stimulated with imdcs copulsed with A27L peptide and zoledronate ( % for CCR7 and % for CD62L; Fig. 6B). The zoledronate-induced adjuvant effects for expanding A27L-specific CD8 T cells using imdcs are higher than that using mdcs Considering the potential application of this for DC therapy in clinical settings, we performed similar experiments using imdcs, which were first cotreated with zoledronate (0.1 M) and A27L peptide (2 g/ml) and then washed extensively before adding to the lymphocytes. The results show that the adjuvant effect on expanding A27L-specific CD8 T cells by Day 14 was similar to that observed when the mixed lymphocyte culture was conducted with zoledronate and A27L peptide in the coculture medium (Figs. 2A and 7A). Parallel experiments were conducted using mdcs instead of imdcs. Figure 7A illustrates that by Day 14, there was approximately a 60-fold increase with imdcs and a two-fold increase with mdcs as the percentage of A27L-specific CD8 T cells once zoledronate was copulsed. The zoledronate-induced adjuvant effects using imdcs were significantly higher than that using mdcs for 7-day culture ( fold expansion with im- DCs vs , with mdcs following copulsing of zoledronate; P 0.012, n 5; Fig. 7B). Fig. 6. (A) IFN- production was only detected in the culture supernatant following h culture of imdcs with autologous lymphocytes in the presence of A27L peptide with zoledronate. imdcs (Donor 6) were cultured with autologous lymphocytes or T cell-depleted lymphocytes at a 1:5 ratio in the presence of A27L peptide, with or without zoledronate for 48 h or 72 h. The level of IFN- in the coculture media was assessed at 48 h and 72 h using ELISA. Data are mean values of triplicate samples. The results are representative of three experiments with similar results. (B) Up-regulation of CCR7 and CD62L molecules on DCs following 48 h culture of imdcs with autologous lymphocytes in the presence of A27L peptide and zoledronate. imdcs were cultured with autologous lymphocytes as described in A. The expression of CCR7 and CD62L was assessed using flow cytometry. The results refer to one representative experiment of three. and zoledronate (not with A27L peptide alone), that the production of IFN- after culture for 48 h was higher than after 72 h, and that this IFN- production did not detect when T cells were depleted from the responding lymphocytes (Fig. 6A). The expression of the lymph node homing receptors, L- selectin (CD62L) and CCR7, on DCs was assessed following culture for 48 h of lymphocytes with imdcs in the presence of Zoledronate enhances imdc-induced expansion of A27L-specific CD8 T cells using apoptotic HLA-A*0201-positive, MART-1-positive JCOCB tumor cell lines as the antigen sources To evaluate adjuvant effects with alternative antigen sources, we evaluated antigen-specific immune responses when apoptotic JCOCB tumor cell lines were used as the antigen source. In these experiments, 40.3% of the JCOCB were shown to be apoptotic based on the numbers of Annexin-V-positive cells (Fig. 8A). The results were similar to those obtained when peptides were used as the antigen source. Specifically, we observed that when imdcs copulsed with zoledronate and apoptotic JCOCB tumor cell lines were used, the percentage of A27L-specific CD8 T cells was higher than that observed using imdcs with apoptotic JCOCB tumor cell lines alone (approximately three- to five-fold higher on 14 days of culture; Fig. 8B). In this experiment, when lymphocytes were cultured with the apoptotic tumor cell lines alone, the percentage of A27L-specific CD8 T cells was %. We observed that when lymphocytes were stimulated with imdcs, copulsed with apoptotic JCOCB tumor cell lines and zoledronate, the 750 Journal of Leukocyte Biology Volume 83, March

10 Fig. 7. Enhancement of tumor antigenspecific CD8 T cells by imdcs copulsed with A27L peptide and zoledronate was higher than that by mdcs copulsed with A27L peptide and zoledronate. (A) imdcs and mdcs (from Donor 7) were cultured separately overnight in the presence or absence of zoledronate (0.1 M) with A27L peptide (2 g/ml). After extensive washing to remove peptide and zoledronate, the DCs were then cocultured with autologous lymphocytes. The percentage of A27L-specific CD8 T cells was assessed on Day 14 by flow cytometry using A27L tetramers. The results are representative of five experiments with similar results. (B) The zoledronate-induced adjuvant effects using imdcs were significantly higher than that using mdcs for 7-day culture ( fold expansion with imdcs vs , with mdcs following copulsing of zoledronate; P 0.012, n 5). DCs (imdcs or mdcs), pulsed with A27L peptide alone or A27L peptide (2 g/ml) plus zoledronate (0.1 M), were cultured with autologous lymphocytes and assessed the percentage of A27L-specific CD8 T cells on Day 7 by flow cytometry using A27L tetramer. MFI of A27L tetramer-positive cells was also increased in comparison with that observed using imdcs pulsed with apoptotic JCOCB tumor cell lines alone (Fig. 8B). DISCUSSION This study demonstrates potent, adjuvant effects of zoledronate on enhancing tumor antigen-specific T cells. We also demonstrate that V 9 T cells activated by zoledronate are pivotal in the adjuvant effects, linking innate and acquired immunity in a way that amplifies activation and proliferation of tumor antigen-specific CD8 T cells. This has a number of important implications, some of which may have a significant impact on the use of aminobisphosphonates in the setting of cancer therapy. The key role of V 9 T cells in the zoledronate-induced adjuvant effects was confirmed by a number of observations. Most significantly, addition of V 9 T cells to a purified population of responding T cells ( 99% purity) in the presence of zoledronate enhanced the effects of zoledronate on induction of A27L-specific CD8 T cells in a dose-dependent manner (Fig. 4A). This finding is strengthened by the additional observation that depletion of V 9 T cells from responding lymphocytes significantly reduced the enhancing effects of zoledronate on induction of A27L-specific CD8 T cells in response to stimulation by imdcs copulsed with zoledronate and A27L peptide (Fig. 4B). The observation that activation of V 9 T cells, resulting in the induction of CD40L on the V 9 T cells on Day 7, occurred prior to higher expansion of A27L-specific CD8 T cells on Day 14 (Fig. 5, A C) provides additional but circumstantial evidence that V 9 T cell activation is a key event in the adjuvant activities of zoledronate on induction of A27L-specific CD8 T cells. CD40 CD40L-mediated activation of antigen-presenting DCs by V 9 T cells may have an important role in the observed, adjuvant effects of zoledronate, as it was previously suggested that CD40 ligation on DCs by CD40L-expressing T cells, such as inkt cells, plays an important role in the linkage of innate to acquired immunity through DCs to induce antigenspecific CD8 T cells [45]. Antigen-specific T cell proliferation was greater following stimulation by imdcs copulsed with zoledronate and A27L peptide than mdcs copulsed with zoledronate and A27L peptide (Fig. 7, A and B). This was initially unexpected but may be linked with the fact that zoledronate-associated expansion of V 9 T cells was greater Fig. 8. Enhancement of A27L-specific CD8 T cells by imdcs copulsed with zoledronate using apoptotic, MART-1-positive, HLA- A*0201-positive JCOCB tumor cell lines as the antigen sources. (A) The percentage of apoptotic cells (40.3% as Annexin-V-positive cells) in the JCOCB tumor cell lines used in this experiment. 7-AAD, 7-Amino-actinomycin. (B) imdcs (Donors 07 and 04) were cultured overnight in the presence or absence of zoledronate at 0.1 M with apoptotic JCOCB tumor cell lines (Tu). The percentage of A27L-specific CD8 T cells (A27L cells) and MFI (M) of those A27Lspecific CD8 T cells were assessed on Day 14 using flow cytometry. The results are representative of seven experiments with similar results. Takahara et al. DCs pulsed with tumor antigen and zoledronate 751

Ex vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2*

Ex vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2* Ex vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2* 1 Department of Laboratory Medicine - Laboratory of Hematology, Radboud University

More information

Supporting Information

Supporting Information Supporting Information Bellora et al. 10.1073/pnas.1007654108 SI Materials and Methods Cells. NK cells purified from peripheral blood mononuclear cells (PBMC) of healthy donors (Human NK Cell Isolation

More information

MATERIALS AND METHODS. Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All

MATERIALS AND METHODS. Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All MATERIALS AND METHODS Antibodies (Abs), flow cytometry analysis and cell lines Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All other antibodies used

More information

Excerpt from MACS&more Vol 17 1/2016. Kenji Miki¹, Koji Nagaoka¹, Hermann Bohnenkamp², Takayuki Yoshimoto³, Ryuji Maekawa¹*, and Takashi Kamigaki⁴

Excerpt from MACS&more Vol 17 1/2016. Kenji Miki¹, Koji Nagaoka¹, Hermann Bohnenkamp², Takayuki Yoshimoto³, Ryuji Maekawa¹*, and Takashi Kamigaki⁴ Excerpt from MCS&more Vol 17 1/2016 Dendritic cells pulsed with induce both OV-specific CD4 + and CD8 + T cells and cause antitumor effects in a mouse model of lymphoma Kenji Miki¹, Koji Nagaoka¹, Hermann

More information

CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205

CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205 AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING

More information

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes

More information

Supplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs

Supplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs Supplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs (idcs) and mature DCs (mdcs). A myeloma cell line expressing

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/23854 holds various files of this Leiden University dissertation. Author: Marel, Sander van der Title: Gene and cell therapy based treatment strategies

More information

Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-

Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone

More information

MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery

MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery Your Partner in Drug Discovery and Research MHC Tetramer Background T-Cell Receptors recognize and bind to complexes composed

More information

Detailed step-by-step operating procedures for NK cell and CTL degranulation assays

Detailed step-by-step operating procedures for NK cell and CTL degranulation assays Supplemental methods Detailed step-by-step operating procedures for NK cell and CTL degranulation assays Materials PBMC isolated from patients, relatives and healthy donors as control K562 cells (ATCC,

More information

NK cell flow cytometric assay In vivo DC viability and migration assay

NK cell flow cytometric assay In vivo DC viability and migration assay NK cell flow cytometric assay 6 NK cells were purified, by negative selection with the NK Cell Isolation Kit (Miltenyi iotec), from spleen and lymph nodes of 6 RAG1KO mice, injected the day before with

More information

Figure S1. Gating strategy used in NK cells and γδ T lymphocytes coculture An example of flow cytometry analysis shows the gating of NK cells and γδ

Figure S1. Gating strategy used in NK cells and γδ T lymphocytes coculture An example of flow cytometry analysis shows the gating of NK cells and γδ Figure S1. Gating strategy used in NK cells and γδ T lymphocytes coculture An example of flow cytometry analysis shows the gating of NK cells and γδ T lymphocytes used in all NK activation and cytotoxicity

More information

CD25-PE (BD Biosciences) and labeled with anti-pe-microbeads (Miltenyi Biotec) for depletion of CD25 +

CD25-PE (BD Biosciences) and labeled with anti-pe-microbeads (Miltenyi Biotec) for depletion of CD25 + Supplements Supplemental Materials and Methods Depletion of CD25 + T-cells from PBMC. Fresh or HD precultured PBMC were stained with the conjugate CD25-PE (BD Biosciences) and labeled with anti-pe-microbeads

More information

Supplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific

Supplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific SUPPLEMENTARY FIGURE LEGEND Supplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific CD4 + T cells correlates with intracellular CTLA-4 levels. (a) Comparative CTLA-4 levels

More information

Commercially available HLA Class II tetramers (Beckman Coulter) conjugated to

Commercially available HLA Class II tetramers (Beckman Coulter) conjugated to Class II tetramer staining Commercially available HLA Class II tetramers (Beckman Coulter) conjugated to PE were combined with dominant HIV epitopes (DRB1*0101-DRFYKTLRAEQASQEV, DRB1*0301- PEKEVLVWKFDSRLAFHH,

More information

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer AD Award Number: W8XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins

More information

Supplemental Information. Human CD1c + Dendritic Cells Drive. the Differentiation of CD103 + CD8 + Mucosal Effector T Cells via the Cytokine TGF-

Supplemental Information. Human CD1c + Dendritic Cells Drive. the Differentiation of CD103 + CD8 + Mucosal Effector T Cells via the Cytokine TGF- Immunity, Volume 38 Supplemental Information Human CD1c + Dendritic Cells Drive the Differentiation of CD103 + CD8 + Mucosal Effector T Cells via the Cytokine TGF- Chun I. Yu Christian Becker Yuanyuan

More information

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke, Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins

More information

Supplementary Data Table of Contents:

Supplementary Data Table of Contents: Supplementary Data Table of Contents: - Supplementary Methods - Supplementary Figures S1(A-B) - Supplementary Figures S2 (A-B) - Supplementary Figures S3 - Supplementary Figures S4(A-B) - Supplementary

More information

Supplementary Figures

Supplementary Figures Supplementary Figures Supplementary Figure 1. NKT ligand-loaded tumour antigen-presenting B cell- and monocyte-based vaccine induces NKT, NK and CD8 T cell responses. (A) The cytokine profiles of liver

More information

Supplementary Figure 1. Efficient DC depletion in CD11c.DOG transgenic mice

Supplementary Figure 1. Efficient DC depletion in CD11c.DOG transgenic mice Supplementary Figure 1. Efficient DC depletion in CD11c.DOG transgenic mice (a) CD11c.DOG transgenic mice (tg) were treated with 8 ng/g body weight (b.w.) diphtheria toxin (DT) i.p. on day -1 and every

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Complete but curtailed T-cell response to very-low-affinity antigen Dietmar Zehn, Sarah Y. Lee & Michael J. Bevan Supp. Fig. 1: TCR chain usage among endogenous K b /Ova reactive T cells. C57BL/6 mice

More information

Principle of the FluoroSpot assay. Anti-tag mab-green. Streptavidin-Red. Detection mab-tag. Detection mab-biotin. Analyte. Analyte.

Principle of the FluoroSpot assay. Anti-tag mab-green. Streptavidin-Red. Detection mab-tag. Detection mab-biotin. Analyte. Analyte. FluoroSpot 1 The principle objective of the FluoroSpot assay is the simultaneous measurement of dual cytokine secretion at the single cell level. This is accomplished by using a mixture of monoclonal antibodies

More information

TCR, MHC and coreceptors

TCR, MHC and coreceptors Cooperation In Immune Responses Antigen processing how peptides get into MHC Antigen processing involves the intracellular proteolytic generation of MHC binding proteins Protein antigens may be processed

More information

In vitro human regulatory T cell expansion

In vitro human regulatory T cell expansion - 1 - Human CD4 + CD25 + regulatory T cell isolation, Workflow in vitro expansion and analysis In vitro human regulatory T cell expansion Introduction Regulatory T (Treg) cells are a subpopulation of T

More information

HCV core protein interaction with gc1q receptor inhibits Th1 differentiation of CD4 T cells via suppression of dendritic cell IL-12 production

HCV core protein interaction with gc1q receptor inhibits Th1 differentiation of CD4 T cells via suppression of dendritic cell IL-12 production HCV core protein interaction with gcq receptor inhibits Th differentiation of CD T cells via suppression of dendritic cell IL- production Stephen N. Waggoner,*, Caroline H. T. Hall,* and Young S. Hahn*,,

More information

In vitro human regulatory T cell expansion

In vitro human regulatory T cell expansion - 1 - Human CD4 + CD25 + CD127 dim/- regulatory T cell Workflow isolation, in vitro expansion and analysis In vitro human regulatory T cell expansion Introduction Regulatory T (Treg) cells are a subpopulation

More information

Mouse DCs were cocultured with ID8-ova lysates, matured and analyzed for CD11c. SIINFEKL-pentamer staining and mouse Treg cell phenoytyping

Mouse DCs were cocultured with ID8-ova lysates, matured and analyzed for CD11c. SIINFEKL-pentamer staining and mouse Treg cell phenoytyping Supplementary Materials and Methods Detection of SIINFEKL-MHC Class I complex on mouse DCs Mouse DCs were cocultured with ID8-ova lysates, matured and analyzed for CD11c (clone N418, Armenian hamster IgG,

More information

Generation of Multiple Peptide Cocktail-Pulsed Dendritic Cells as a Cancer Vaccine

Generation of Multiple Peptide Cocktail-Pulsed Dendritic Cells as a Cancer Vaccine Chapter 2 Generation of Multiple Peptide Cocktail-Pulsed Dendritic Cells as a Cancer Vaccine Hyun-Ju Lee, Nu-Ri Choi, Manh-Cuong Vo, My-Dung Hoang, Youn-Kyung Lee, and Je-Jung Lee Abstract Cancer immunotherapy

More information

IFN-γ Secretion Assay Detection Kit (PE) human

IFN-γ Secretion Assay Detection Kit (PE) human Miltenyi Biotec GmbH Friedrich-Ebert-Straße 68 51429 Bergisch Gladbach, Germany Phone +49 2204 8306-0 Fax +49 2204 85197 macs@miltenyibiotec.de Miltenyi Biotec Inc. 12740 Earhart Avenue Auburn CA 95602,

More information

Optimizing Intracellular Flow Cytometry:

Optimizing Intracellular Flow Cytometry: Optimizing Intracellular Flow Cytometry: Simultaneous Detection of Cytokines and Transcription Factors An encore presentation by Jurg Rohrer, PhD, BD Biosciences 10.26.10 Outline Introduction Cytokines

More information

T cell-mediated immunity

T cell-mediated immunity T cell-mediated immunity Overview For microbes within phagosomes in phagocytes.cd4+ T lymphocytes (TH1) Activate phagocyte by cytokines studies on Listeria monocytogenes For microbes infecting and replicating

More information

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke,. CONTRACTING ORGANIZATION: Johns Hopkins

More information

The Adaptive Immune Responses

The Adaptive Immune Responses The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start

More information

Immune surveillance: The immune system can recognize and destroy nascent malignant cells

Immune surveillance: The immune system can recognize and destroy nascent malignant cells Immune surveillance: The immune system can recognize and destroy nascent malignant cells Control Escape APC T C T H B NKT NK Innate Tumor T cells are believed to play a major role in controlling tumor

More information

Naive, memory and regulatory T lymphocytes populations analysis

Naive, memory and regulatory T lymphocytes populations analysis Naive, memory and regulatory T lymphocytes populations analysis Jaen Olivier, PhD ojaen@beckmancoulter.com Cellular Analysis application specialist Beckman Coulter France Introduction Flow cytometric analysis

More information

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be

More information

Supplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in

Supplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in Supplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in Supplementary Fig. 2 Substitution Sequence Position variant Sequence original APNCYGNIPL original APNCYGNIPL

More information

Supplementary Figure 1. Example of gating strategy

Supplementary Figure 1. Example of gating strategy Supplementary Figure 1. Example of gating strategy Legend Supplementary Figure 1: First, gating is performed to include only single cells (singlets) (A) and CD3+ cells (B). After gating on the lymphocyte

More information

Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells

Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Sharon A. Riddler, MD, MPH University of Pittsburgh May 2008 Slide 1 HIV and DC Vaccines During

More information

a Beckman Coulter Life Sciences: White Paper

a Beckman Coulter Life Sciences: White Paper a Beckman Coulter Life Sciences: White Paper An 8-color DuraClone IM panel for detection of Human blood dendritic cells by flow cytometry Nathalie Dupas 1, Snehita Sattiraju 2, Neha Girish 2, Murthy Pendyala

More information

Supplementary Data. Treg phenotype

Supplementary Data. Treg phenotype Supplementary Data Additional Experiment An additional experiment was performed using cryopreserved peripheral blood mononuclear cells (PBMC) derived from five renal cell carcinoma (RCC) patients [see

More information

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS 1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family

More information

Cytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands

Cytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Cytotoxicity assays Rory D. de Vries, PhD 1 1 Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Anti-influenza immunity Humoral / CD4+ / CD8+ / NK? Function of CTL Elimination of virus-infected cells?

More information

HLA-DR+ Immature Cells Exhibit Reduced Antigen- Presenting Cell Function But Respond to CD40 Stimulation

HLA-DR+ Immature Cells Exhibit Reduced Antigen- Presenting Cell Function But Respond to CD40 Stimulation HLA-DR+ Immature Cells Exhibit Reduced Antigen- Presenting Cell Function But Respond to CD40 Stimulation Author Pinzon-Charry, Alberto, Maxwell, Tammy, Prato, Sandro, Furnival, Colin, Schmidt, Chris, Lopez,

More information

Cell Mediated Immunity CELL MEDIATED IMMUNITY. Basic Elements of Cell Mediated Immunity (CMI) Antibody-dependent cell-mediated cytotoxicity (ADCC)

Cell Mediated Immunity CELL MEDIATED IMMUNITY. Basic Elements of Cell Mediated Immunity (CMI) Antibody-dependent cell-mediated cytotoxicity (ADCC) Chapter 16 CELL MEDIATED IMMUNITY Cell Mediated Immunity Also known as Cellular Immunity or CMI The effector phase T cells Specificity for immune recognition reactions TH provide cytokines CTLs do the

More information

Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE)

Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE) Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central

More information

CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205

CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205 AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING

More information

Adaptive immune responses: T cell-mediated immunity

Adaptive immune responses: T cell-mediated immunity MICR2209 Adaptive immune responses: T cell-mediated immunity Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will discuss the T-cell mediated immune response, how it is activated,

More information

Supplementary Fig. 1: Ex vivo tetramer enrichment with anti-c-myc beads

Supplementary Fig. 1: Ex vivo tetramer enrichment with anti-c-myc beads Supplementary Fig. 1: Ex vivo tetramer enrichment with anti-c-myc beads Representative example of comparative ex vivo tetramer enrichment performed in three independent experiments with either conventional

More information

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells ICI Basic Immunology course Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells Abul K. Abbas, MD UCSF Stages in the development of T cell responses: induction

More information

PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human

PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human Anti-CD19-CAR transduced T-cell preparation PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human AB serum (Gemini) and 300 international units/ml IL-2 (Novartis). T cell proliferation

More information

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.

More information

Natural Killer Cells: Development, Diversity, and Applications to Human Disease Dr. Michael A. Caligiuri

Natural Killer Cells: Development, Diversity, and Applications to Human Disease Dr. Michael A. Caligiuri Natural Killer Cells: Development, Diversity, November 26, 2008 The Ohio State University Comprehensive Cancer Center The James Cancer Hospital and Solove Research Institute Columbus, Ohio, USA 1 Human

More information

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features Loretta Gammaitoni, Lidia Giraudo, Valeria Leuci, et al. Clin Cancer Res

More information

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer) Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of

More information

Measuring Dendritic Cells

Measuring Dendritic Cells Measuring Dendritic Cells A.D. Donnenberg, V.S. Donnenberg UNIVERSITY of PITTSBURGH CANCER INSTITUTE CCS Longbeach 10_04 Measuring DC Rare event detection The basics of DC measurement Applications Cancer

More information

Supplemental Figure 1. IL-3 blockade with Fab CSL362 depletes plasmacytoid dendritic cells (pdcs), but not basophils, at higher doses.

Supplemental Figure 1. IL-3 blockade with Fab CSL362 depletes plasmacytoid dendritic cells (pdcs), but not basophils, at higher doses. Supplemental Figure 1. IL-3 blockade with Fab CSL362 depletes plasmacytoid dendritic cells (pdcs), but not basophils, at higher doses. Percentage of viable (A) pdcs (Sytox Blue-, Lin1-, HLADR+, BDCA2++)

More information

Application Information Bulletin: Human NK Cells Phenotypic characterizing of human Natural Killer (NK) cell populations in peripheral blood

Application Information Bulletin: Human NK Cells Phenotypic characterizing of human Natural Killer (NK) cell populations in peripheral blood Application Information Bulletin: Human NK Cells Phenotypic characterizing of human Natural Killer (NK) cell populations in peripheral blood Christopher A Fraker, Ph.D., University of Miami - Miami, Florida

More information

Supplemental Figure 1. Signature gene expression in in vitro differentiated Th0, Th1, Th2, Th17 and Treg cells. (A) Naïve CD4 + T cells were cultured

Supplemental Figure 1. Signature gene expression in in vitro differentiated Th0, Th1, Th2, Th17 and Treg cells. (A) Naïve CD4 + T cells were cultured Supplemental Figure 1. Signature gene expression in in vitro differentiated Th0, Th1, Th2, Th17 and Treg cells. (A) Naïve CD4 + T cells were cultured under Th0, Th1, Th2, Th17, and Treg conditions. mrna

More information

Dendritic cells in cancer immunotherapy Aimin Jiang

Dendritic cells in cancer immunotherapy Aimin Jiang Dendritic cells in cancer immunotherapy Aimin Jiang Feb. 11, 2014 Dendritic cells at the interface of innate and adaptive immune responses Dendritic cells: initiators of adaptive immune responses Dendritic

More information

B6/COLODR/SPL/11C/83/LAP/#2.006 B6/COLODR/SPL/11C/86/LAP/#2.016 CD11C B6/COLODR/SPL/11C/80/LAP/#2.011 CD11C

B6/COLODR/SPL/11C/83/LAP/#2.006 B6/COLODR/SPL/11C/86/LAP/#2.016 CD11C B6/COLODR/SPL/11C/80/LAP/#2.011 CD11C CD3-specific antibody-induced immune tolerance and suppression of autoimmune encephalomyelitis involves TGF-β production through phagocytes digesting apoptotic T cells Sylvain Perruche 1,3, Pin Zhang 1,

More information

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses

More information

Automated manufacture of T-cell immunotherapies using gamma retroviral transduction. Lee Markwick, PhD. AMC, Manchester March 2018

Automated manufacture of T-cell immunotherapies using gamma retroviral transduction. Lee Markwick, PhD. AMC, Manchester March 2018 Automated manufacture of T-cell immunotherapies using gamma retroviral transduction Lee Markwick, PhD AMC, Manchester March 2018 Automated generation of CAR T cells Starting material d0 T cell enrichment

More information

In vitro human regulatory T cell suppression assay

In vitro human regulatory T cell suppression assay Human CD4 + CD25 + regulatory T cell isolation, in vitro suppression assay and analysis In vitro human regulatory T cell suppression assay Introduction Regulatory T (Treg) cells are a subpopulation of

More information

Chapter 10 (pages ): Differentiation and Functions of CD4+ Effector T Cells Prepared by Kristen Dazy, MD, Scripps Clinic Medical Group

Chapter 10 (pages ): Differentiation and Functions of CD4+ Effector T Cells Prepared by Kristen Dazy, MD, Scripps Clinic Medical Group FIT Board Review Corner September 2015 Welcome to the FIT Board Review Corner, prepared by Andrew Nickels, MD, and Sarah Spriet, DO, senior and junior representatives of ACAAI's Fellows-In-Training (FITs)

More information

Vasoactive intestinal peptide inhibits IFN-α secretion and modulates the immune function of plasmacytoid dendritic cells

Vasoactive intestinal peptide inhibits IFN-α secretion and modulates the immune function of plasmacytoid dendritic cells Excerpt from MACS&more Vol 12 1/21 Vasoactive intestinal peptide inhibits IFN-α secretion and modulates the immune function of plasmacytoid dendritic cells Dorit Fabricius 1, 2,, M. Sue O Dorisio 1, 2,

More information

Cover Page. The handle holds various files of this Leiden University dissertation

Cover Page. The handle   holds various files of this Leiden University dissertation Cover Page The handle http://hdl.handle.net/1887/24366 holds various files of this Leiden University dissertation Author: Buddingh, Emilie Pauline Title: Innate immunity in osteosarcoma Issue Date: 2014-03-05

More information

CD14 + S100A9 + Monocytic Myeloid-Derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer

CD14 + S100A9 + Monocytic Myeloid-Derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer CD14 + S1A9 + Monocytic Myeloid-Derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer Po-Hao, Feng M.D., Kang-Yun, Lee, M.D. Ph.D., Ya-Ling Chang, Yao-Fei Chan, Lu- Wei, Kuo,Ting-Yu

More information

CHAPTER 3 LABORATORY PROCEDURES

CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified

More information

Rapid antigen-specific T cell enrichment (Rapid ARTE)

Rapid antigen-specific T cell enrichment (Rapid ARTE) Direct ex vivo characterization of human antigen-specific CD154+CD4+ T cell Rapid antigen-specific T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central role

More information

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?

More information

CD40L TCR IL-12 TLR-L

CD40L TCR IL-12 TLR-L CD40L B cells plasmacells Neutrophils TCR inkt cells IL-12 Ab production Can inkt cells modulate the cytokine profile of neutrophils? TLR-L CD4+ and CD8+ T cell responses 1. The invariant TCR expressed

More information

NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Rα

NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Rα Research article NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Rα Fabienne Brilot, Till Strowig, Susanne M. Roberts, Frida Arrey, and Christian Münz Laboratory of

More information

Supplementary Table e-1. Flow cytometry reagents and staining combinations

Supplementary Table e-1. Flow cytometry reagents and staining combinations Supplementary data Supplementary Table e-1. Flow cytometry reagents and staining combinations Reagents Antibody Fluorochrome Clone Source conjugation CD3 FITC UCHT1 BD Biosciences CD3 PerCP-Cy5.5 SK7 Biolegend

More information

08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells

08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines

More information

MAIT cell function is modulated by PD-1 signaling in patients with active

MAIT cell function is modulated by PD-1 signaling in patients with active MAIT cell function is modulated by PD-1 signaling in patients with active tuberculosis Jing Jiang, M.D., Xinjing Wang, M.D., Hongjuan An, M.Sc., Bingfen Yang, Ph.D., Zhihong Cao, M.Sc., Yanhua Liu, Ph.D.,

More information

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard

More information

ImageStream cytometer analysis. Cells were cultured as described above in vented-cap

ImageStream cytometer analysis. Cells were cultured as described above in vented-cap ImageStream cytometer analysis. Cells were cultured as described above in vented-cap polypropylene tubes, stained with αcd66b-fitc, αm-dc8-pe and αcd56-pe-cy5.5 mabs, washed and fixed with 4 % (w/v) paraformaldehyde.

More information

were isolated from the freshly drawn blood of healthy donors and ACS patients using the

were isolated from the freshly drawn blood of healthy donors and ACS patients using the Supplemental Figure 1. Quality control of CD4 + T-cell purification. CD4 + T cells were isolated from the freshly drawn blood of healthy donors and ACS patients using the RosetteSep CD4 + T Cell Enrichment

More information

Supplemental Table I.

Supplemental Table I. Supplemental Table I Male / Mean ± SEM n Mean ± SEM n Body weight, g 29.2±0.4 17 29.7±0.5 17 Total cholesterol, mg/dl 534.0±30.8 17 561.6±26.1 17 HDL-cholesterol, mg/dl 9.6±0.8 17 10.1±0.7 17 Triglycerides,

More information

RAISON D ETRE OF THE IMMUNE SYSTEM:

RAISON D ETRE OF THE IMMUNE SYSTEM: RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense

More information

Supplemental Figure 1. Activated splenocytes upregulate Serpina3g and Serpina3f expression.

Supplemental Figure 1. Activated splenocytes upregulate Serpina3g and Serpina3f expression. Relative Serpin expression 25 2 15 1 5 Serpina3f 1 2 3 4 5 6 8 6 4 2 Serpina3g 1 2 3 4 5 6 C57BL/6 DBA/2 Supplemental Figure 1. Activated splenocytes upregulate Serpina3g and Serpina3f expression. Splenocytes

More information

Natural Killer T Cells Are Critical for Dendritic Cells to Induce Immunity in Chlamydial Pneumonia

Natural Killer T Cells Are Critical for Dendritic Cells to Induce Immunity in Chlamydial Pneumonia Natural Killer T Cells Are Critical for Dendritic Cells to Induce Immunity in Chlamydial Pneumonia Antony George Joyee 1, Hongyu Qiu 1, Yijun Fan 1, Shuhe Wang 1, and Xi Yang 1 1 Laboratory for Infection

More information

In the last decade, dendritic cell (DC)-based immunotherapy

In the last decade, dendritic cell (DC)-based immunotherapy CLINICAL STUDY Cryopreservation of Monocytes Is Superior to Cryopreservation of Immature or Semi-mature Dendritic Cells for Dendritic Cell-based Immunotherapy Hubert Hayden,* Josef Friedl,* Markus Dettke,w

More information

Supplementary Figure 1. IL-12 serum levels and frequency of subsets in FL patients. (A) IL-12

Supplementary Figure 1. IL-12 serum levels and frequency of subsets in FL patients. (A) IL-12 1 Supplementary Data Figure legends Supplementary Figure 1. IL-12 serum levels and frequency of subsets in FL patients. (A) IL-12 serum levels measured by multiplex ELISA (Luminex) in FL patients before

More information

PRIME-XV Dendritic Cell Maturation CDM

PRIME-XV Dendritic Cell Maturation CDM PRIME-XV Dendritic Cell Maturation CDM Chemically defined, animal component-free medium for dendritic cell culture Optimized for differentiation of monocytes into immature dendritic cells (idcs) and subsequent

More information

Structure and Function of Antigen Recognition Molecules

Structure and Function of Antigen Recognition Molecules MICR2209 Structure and Function of Antigen Recognition Molecules Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will examine the major receptors used by cells of the innate and

More information

Test Bank for Basic Immunology Functions and Disorders of the Immune System 4th Edition by Abbas

Test Bank for Basic Immunology Functions and Disorders of the Immune System 4th Edition by Abbas Test Bank for Basic Immunology Functions and Disorders of the Immune System 4th Edition by Abbas Chapter 04: Antigen Recognition in the Adaptive Immune System Test Bank MULTIPLE CHOICE 1. Most T lymphocytes

More information

Human Innate Lymphoid Cells: crosstalk with CD4 + regulatory T cells and role in Type 1 Diabetes

Human Innate Lymphoid Cells: crosstalk with CD4 + regulatory T cells and role in Type 1 Diabetes Joint Lab Meeting 03/03/2015 Human Innate Lymphoid Cells: crosstalk with CD4 + regulatory T cells and role in Type 1 Diabetes Caroline Raffin Bluestone Lab ILCs: Definition - Common lymphoid progenitor

More information

Advances in Cancer Immunotherapy

Advances in Cancer Immunotherapy Advances in Cancer Immunotherapy Immunology 101 for the Non-Immunologist Arnold H. Zea, PhD azea@lsuhsc.edu Disclosures No relevant financial relationships to disclose This presentation does not contain

More information

TITLE: Fusions of Breast Carcinoma and Dendritic Cells as a Vaccine for the Treatment of Metatastic Breast Cancer

TITLE: Fusions of Breast Carcinoma and Dendritic Cells as a Vaccine for the Treatment of Metatastic Breast Cancer AD Award Number: DAMD17-03-1-0487 TITLE: Fusions of Breast Carcinoma and Dendritic Cells as a Vaccine for the Treatment of Metatastic Breast Cancer PRINCIPAL INVESTIGATOR: Donald Kufe, M.D. CONTRACTING

More information

System Biology analysis of innate and adaptive immune responses during HIV infection

System Biology analysis of innate and adaptive immune responses during HIV infection System Biology analysis of innate and adaptive immune responses during HIV infection Model of T cell memory persistence and exhaustion Naive Ag+APC Effector TEM (Pfp, Gr.B, FasL, TNF) Ag stim. IL-2, IL-7,

More information

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and

More information

ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY

ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY The recognition of specific antigen by naïve T cell induces its own activation and effector phases. T helper cells recognize peptide antigens through

More information

Supplementary Figure 1. Using DNA barcode-labeled MHC multimers to generate TCR fingerprints

Supplementary Figure 1. Using DNA barcode-labeled MHC multimers to generate TCR fingerprints Supplementary Figure 1 Using DNA barcode-labeled MHC multimers to generate TCR fingerprints (a) Schematic overview of the workflow behind a TCR fingerprint. Each peptide position of the original peptide

More information

Optimizing Intracellular Flow Cytometry

Optimizing Intracellular Flow Cytometry Optimizing Intracellular Flow Cytometry Detection of Cytokines, Transcription Factors, and Phosphoprotein by Flow Cytometry Presented by Erika O Donnell, PhD, BD Biosciences 23-14876-00 Outline Basic principles

More information

Cancer Biometrics: Results of the 2003 isbtc Workshop. Theresa L. Whiteside, Ph.D., ABMLI University of Pittsburgh Cancer Institute

Cancer Biometrics: Results of the 2003 isbtc Workshop. Theresa L. Whiteside, Ph.D., ABMLI University of Pittsburgh Cancer Institute Cancer Biometrics: Results of the 2003 isbtc Workshop Theresa L. Whiteside, Ph.D., ABMLI University of Pittsburgh Cancer Institute The workshop objective The objective was to consider state-of-theart approaches

More information

Supplementalgfigureg1gSchematicgdiagramgofgtumor1modellingg

Supplementalgfigureg1gSchematicgdiagramgofgtumor1modellingg SChinjectionh F:LuchLCLsh IVhinjectionh T:cellsh Monitorhforhtumorh growthhandhxeno: reactivehgvhd GVLgexperimentg kcbgvsgpbgt1cellse Xeno1reactiveg experimentg kcbgvsgpbgt1cellse IVhinjectionh 5xh,N^6

More information